同源康医药-B(02410.HK)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评

Core Viewpoint - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced that its investigational first-class new drug, Tyrosine Kinase Inhibitor (TY-9591), has been proposed for inclusion in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - The proposed indication for TY-9591 is for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1]